Stockscreener 앱 받기
0.5751
6.32%
-0.0388
시장 영업 전:
.56
-0.0151
-2.63%
전일 마감가:
$0.6139
열려 있는:
$0.6
하루 거래량:
252.45K
Relative Volume:
0.14
시가총액:
$3.50M
수익:
$35.52M
순이익/손실:
$11.39M
주가수익비율:
-0.00728
EPS:
-78.9878
순현금흐름:
$-26.04M
1주 성능:
-11.52%
1개월 성능:
-4.13%
6개월 성능:
-33.90%
1년 성능:
-61.66%
1일 변동 폭
$0.56
$0.60
1주일 범위
$0.56
$0.7097
52주 변동 폭
$0.56
$2.79
레드힐 바이오파마 ADR Stock (RDHL) Company Profile
명칭
Redhill Biopharma Ltd Adr
전화
-
주소
-
Compare RDHL vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
0.5751 | 3.92M | 35.52M | 11.39M | -26.04M | -78.99 |
TAK
Takeda Pharmaceutical Co Adr
|
18.70 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.25 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.24 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.43 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
500.35 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
레드힐 바이오파마 ADR Stock (RDHL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-08-31 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-18 | 개시 | H.C. Wainwright | Buy |
| 2020-09-11 | 개시 | BTIG Research | Buy |
| 2019-07-12 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | 개시 | Nomura | Buy |
| 2017-10-06 | 개시 | Seaport Global Securities | Buy |
| 2017-10-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-24 | 재확인 | FBR & Co. | Outperform |
| 2016-07-27 | 재확인 | FBR Capital | Outperform |
| 2015-09-29 | 개시 | Nomura | Buy |
| 2015-07-29 | 재확인 | ROTH Capital | Buy |
| 2015-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-15 | 재확인 | ROTH Capital | Buy |
모두보기
레드힐 바이오파마 ADR 주식(RDHL)의 최신 뉴스
Redhill Biopharma Ltd.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
RedHill acquires rights to two GI drugs from Ferring for $12M - Investing.com Nigeria
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq® - Barchart.com
RedHill Biopharma Sells Talicia to Apotex for $18M Upfront Plus $35M in Potential Milestones - kalkinemedia.com
Can RedHill Biopharma (NASDAQ:RDHL) Show Commercial Progress Today? - Kalkine Media
Ebola Cases and Deaths Rapidly MountRedHill Updates on Opaganib Emergency Outbreak Development - Sahm
RedHill Biopharma Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:RDHL) - TradingView
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement - Sahm
RedHill Biopharma closes $6 million private placement - Investing.com
RedHill Biopharma closes $6 million private placement By Investing.com - Investing.com South Africa
Form 6K Redhill Biopharma Ltd For: 22 June By Investing.com - Investing.com Nigeria
Form 6K RedHill Biopharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
RedHill Biopharma raises $6M in private placement - Investing.com
RedHill Biopharma raises $6M in private placement By Investing.com - Investing.com South Africa
RedHill Biopharma Announces Up To $19.4 Million Private Placement - Barchart.com
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
RedHill Biopharma begins Korea enforcement of $10.9M judgment By Investing.com - Investing.com South Africa
RedHill Biopharma begins Korea enforcement of $10.9M judgment - Investing.com
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo - Barchart.com
RDHL News | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - ChartMill
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms - Sahm
RDHL - Finviz
Redhill Biopharma stock soars on GLP-1 side effect treatment progress - Investing.com Nigeria
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104Important Step in RHB-204 Development for MAP-related Crohn's Disease - ChartMill
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights - Sahm
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical StudiesNew Data Presented at AACR 2026 - ChartMill
RDHL Stock Price, Quote & Chart | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - ChartMill
Crohn’s Disease Treatment Pipeline Shows Strong Momentum as 90+ Pharma Companies in the Race | DelveInsight - Barchart.com
RedHill Biopharma receives Nasdaq notice on minimum bid price requirement By Investing.com - Investing.com South Africa
RedHill Biopharma receives Nasdaq notice on minimum bid price requirement - Investing.com India
Adi Frish details equity holdings in RedHill Biopharma (RDHL) Form 3 - Stock Titan
RDHL Earnings History & Surprises | EPS & Revenue Results | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - ChartMill
Joint U.S. Commercialization of RedHill's Talicia® Commences - Barchart.com
RedHill Biopharma Calls March 5, 2026 Extraordinary Meeting to Approve RSU Grants and Share Capital Increase - The Globe and Mail
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - Benzinga
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - Barchart.com
Redhill Biopharma stock jumps after court win against Kukbo - Investing.com UK
RedHill Biopharma to appeal Nasdaq compliance notice - Investing.com
RedHill Biopharma stock surges after court upholds $10M judgment By Investing.com - Investing.com UK
RDHL: Revenue up 59% and gross profit doubled, but going concern risk persists amid funding shortfall - TradingView
Get insights into the top gainers and losers of Monday's after-hours session. - ChartMill
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win - Finviz
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
RDHL: Net loss, cash burn, and loss of key revenue source put RedHill Biopharma's future at risk - TradingView
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com UK
Redhill Biopharma stock hits 52-week low at $4.79 By Investing.com - Investing.com India
RedHill stock rises on expanded Medicare coverage - Investing.com
JUNS Stock Quote Price and Forecast - CNN
RDHL: Net loss narrowed on an adjusted basis as cost cuts and pipeline progress offset lower revenues - TradingView
레드힐 바이오파마 ADR (RDHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.44%
3.02%
자본화:
|
볼륨(24시간):